Clinical use of micafungin for the treatment of invasive candidiasis in critical ill patients
Over the last 30 years a significant increase of Candida spp. invasive disease has been observed in non-neutropenic critical ill patients. Both fluconazole and amphotericin B have been considered first line treatment for invasive (proven and probable) Candida spp. disease, although the mortality rat...
Gespeichert in:
| Veröffentlicht in: | Revista iberoamericana de micología 2009-03, Vol.26 (1), p.69-74 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | spa |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 74 |
|---|---|
| container_issue | 1 |
| container_start_page | 69 |
| container_title | Revista iberoamericana de micología |
| container_volume | 26 |
| creator | Pozo-Laderas, Juan Carlos |
| description | Over the last 30 years a significant increase of Candida spp. invasive disease has been observed in non-neutropenic critical ill patients. Both fluconazole and amphotericin B have been considered first line treatment for invasive (proven and probable) Candida spp. disease, although the mortality rate is still high.
To review the current data on the use of micafungin for the treatment of Candida invasive disease in critical ill patients.
The pharmacologic, mycological and clinical properties of micafungin are reviewed based on current published data. The use and efficacy of micafungin for the treatment of Candida invasive disease in critical ill patients is discussed.
To reduce the rate of mortality more effective antifungals and pre-emptive treatment strategies are currently warranted. Candins achieve better results for the treatment of invasive Candida disease in non-neutropenic critical ill patients. Micafungin has a good safety profile (similar to fluconazole). Micafungin is a first line drug for the treatment of invasive Candida disease and may be used as a pre- emptive approach followed by a de-escalating strategy with azoles. |
| doi_str_mv | 10.1016/S1130-1406(09)70012-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_20684051</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20684051</sourcerecordid><originalsourceid>FETCH-LOGICAL-p170t-288d0958334e73a5ae05d362ecca402d833787ff9ff14b452e866021e744df523</originalsourceid><addsrcrecordid>eNo9kMtOwzAURL0A0VL4BJBXCBaBe23HSZaoKg-pEgtgiSI3uQYj50HsVOLvCVBYjWbmaBbD2AnCJQLqq0dECQkq0OdQXGQAKJJij83_4xk7DOEdQGhAPGAzLJSWIsc5e1l617rKeD4G4p3lzWTs2L66lttu4PGNeBzIxIba-N27dmuC2xKvTFu72k0mTCGvBhd_dpz3vDfRTXw4YvvW-EDHO12w55vV0_IuWT_c3i-v10mPGcRE5HkNRZpLqSiTJjUEaS21oKoyCkQ9FVmeWVtYi2qjUkG51iCQMqVqmwq5YGe_u_3QfYwUYtm4UJH3pqVuDKUAnStIcQJPd-C4aagu-8E1Zvgs_w6RXzcYYW8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20684051</pqid></control><display><type>article</type><title>Clinical use of micafungin for the treatment of invasive candidiasis in critical ill patients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Pozo-Laderas, Juan Carlos</creator><creatorcontrib>Pozo-Laderas, Juan Carlos</creatorcontrib><description>Over the last 30 years a significant increase of Candida spp. invasive disease has been observed in non-neutropenic critical ill patients. Both fluconazole and amphotericin B have been considered first line treatment for invasive (proven and probable) Candida spp. disease, although the mortality rate is still high.
To review the current data on the use of micafungin for the treatment of Candida invasive disease in critical ill patients.
The pharmacologic, mycological and clinical properties of micafungin are reviewed based on current published data. The use and efficacy of micafungin for the treatment of Candida invasive disease in critical ill patients is discussed.
To reduce the rate of mortality more effective antifungals and pre-emptive treatment strategies are currently warranted. Candins achieve better results for the treatment of invasive Candida disease in non-neutropenic critical ill patients. Micafungin has a good safety profile (similar to fluconazole). Micafungin is a first line drug for the treatment of invasive Candida disease and may be used as a pre- emptive approach followed by a de-escalating strategy with azoles.</description><identifier>ISSN: 1130-1406</identifier><identifier>DOI: 10.1016/S1130-1406(09)70012-9</identifier><identifier>PMID: 19463281</identifier><language>spa</language><publisher>Spain</publisher><subject>Antifungal Agents - administration & dosage ; Antifungal Agents - adverse effects ; Antifungal Agents - therapeutic use ; Candida ; Candidiasis - drug therapy ; Candidiasis - epidemiology ; Clinical Trials as Topic - statistics & numerical data ; Critical Care ; Critical Illness ; Drug Therapy, Combination ; Echinocandins - administration & dosage ; Echinocandins - adverse effects ; Echinocandins - therapeutic use ; Fungemia - drug therapy ; Humans ; Incidence ; Leukocyte Count ; Lipopeptides - administration & dosage ; Lipopeptides - adverse effects ; Lipopeptides - therapeutic use ; Neutrophils ; Randomized Controlled Trials as Topic - statistics & numerical data</subject><ispartof>Revista iberoamericana de micología, 2009-03, Vol.26 (1), p.69-74</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19463281$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pozo-Laderas, Juan Carlos</creatorcontrib><title>Clinical use of micafungin for the treatment of invasive candidiasis in critical ill patients</title><title>Revista iberoamericana de micología</title><addtitle>Rev Iberoam Micol</addtitle><description>Over the last 30 years a significant increase of Candida spp. invasive disease has been observed in non-neutropenic critical ill patients. Both fluconazole and amphotericin B have been considered first line treatment for invasive (proven and probable) Candida spp. disease, although the mortality rate is still high.
To review the current data on the use of micafungin for the treatment of Candida invasive disease in critical ill patients.
The pharmacologic, mycological and clinical properties of micafungin are reviewed based on current published data. The use and efficacy of micafungin for the treatment of Candida invasive disease in critical ill patients is discussed.
To reduce the rate of mortality more effective antifungals and pre-emptive treatment strategies are currently warranted. Candins achieve better results for the treatment of invasive Candida disease in non-neutropenic critical ill patients. Micafungin has a good safety profile (similar to fluconazole). Micafungin is a first line drug for the treatment of invasive Candida disease and may be used as a pre- emptive approach followed by a de-escalating strategy with azoles.</description><subject>Antifungal Agents - administration & dosage</subject><subject>Antifungal Agents - adverse effects</subject><subject>Antifungal Agents - therapeutic use</subject><subject>Candida</subject><subject>Candidiasis - drug therapy</subject><subject>Candidiasis - epidemiology</subject><subject>Clinical Trials as Topic - statistics & numerical data</subject><subject>Critical Care</subject><subject>Critical Illness</subject><subject>Drug Therapy, Combination</subject><subject>Echinocandins - administration & dosage</subject><subject>Echinocandins - adverse effects</subject><subject>Echinocandins - therapeutic use</subject><subject>Fungemia - drug therapy</subject><subject>Humans</subject><subject>Incidence</subject><subject>Leukocyte Count</subject><subject>Lipopeptides - administration & dosage</subject><subject>Lipopeptides - adverse effects</subject><subject>Lipopeptides - therapeutic use</subject><subject>Neutrophils</subject><subject>Randomized Controlled Trials as Topic - statistics & numerical data</subject><issn>1130-1406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kMtOwzAURL0A0VL4BJBXCBaBe23HSZaoKg-pEgtgiSI3uQYj50HsVOLvCVBYjWbmaBbD2AnCJQLqq0dECQkq0OdQXGQAKJJij83_4xk7DOEdQGhAPGAzLJSWIsc5e1l617rKeD4G4p3lzWTs2L66lttu4PGNeBzIxIba-N27dmuC2xKvTFu72k0mTCGvBhd_dpz3vDfRTXw4YvvW-EDHO12w55vV0_IuWT_c3i-v10mPGcRE5HkNRZpLqSiTJjUEaS21oKoyCkQ9FVmeWVtYi2qjUkG51iCQMqVqmwq5YGe_u_3QfYwUYtm4UJH3pqVuDKUAnStIcQJPd-C4aagu-8E1Zvgs_w6RXzcYYW8</recordid><startdate>20090331</startdate><enddate>20090331</enddate><creator>Pozo-Laderas, Juan Carlos</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>M7N</scope></search><sort><creationdate>20090331</creationdate><title>Clinical use of micafungin for the treatment of invasive candidiasis in critical ill patients</title><author>Pozo-Laderas, Juan Carlos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p170t-288d0958334e73a5ae05d362ecca402d833787ff9ff14b452e866021e744df523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>spa</language><creationdate>2009</creationdate><topic>Antifungal Agents - administration & dosage</topic><topic>Antifungal Agents - adverse effects</topic><topic>Antifungal Agents - therapeutic use</topic><topic>Candida</topic><topic>Candidiasis - drug therapy</topic><topic>Candidiasis - epidemiology</topic><topic>Clinical Trials as Topic - statistics & numerical data</topic><topic>Critical Care</topic><topic>Critical Illness</topic><topic>Drug Therapy, Combination</topic><topic>Echinocandins - administration & dosage</topic><topic>Echinocandins - adverse effects</topic><topic>Echinocandins - therapeutic use</topic><topic>Fungemia - drug therapy</topic><topic>Humans</topic><topic>Incidence</topic><topic>Leukocyte Count</topic><topic>Lipopeptides - administration & dosage</topic><topic>Lipopeptides - adverse effects</topic><topic>Lipopeptides - therapeutic use</topic><topic>Neutrophils</topic><topic>Randomized Controlled Trials as Topic - statistics & numerical data</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pozo-Laderas, Juan Carlos</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><jtitle>Revista iberoamericana de micología</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pozo-Laderas, Juan Carlos</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical use of micafungin for the treatment of invasive candidiasis in critical ill patients</atitle><jtitle>Revista iberoamericana de micología</jtitle><addtitle>Rev Iberoam Micol</addtitle><date>2009-03-31</date><risdate>2009</risdate><volume>26</volume><issue>1</issue><spage>69</spage><epage>74</epage><pages>69-74</pages><issn>1130-1406</issn><abstract>Over the last 30 years a significant increase of Candida spp. invasive disease has been observed in non-neutropenic critical ill patients. Both fluconazole and amphotericin B have been considered first line treatment for invasive (proven and probable) Candida spp. disease, although the mortality rate is still high.
To review the current data on the use of micafungin for the treatment of Candida invasive disease in critical ill patients.
The pharmacologic, mycological and clinical properties of micafungin are reviewed based on current published data. The use and efficacy of micafungin for the treatment of Candida invasive disease in critical ill patients is discussed.
To reduce the rate of mortality more effective antifungals and pre-emptive treatment strategies are currently warranted. Candins achieve better results for the treatment of invasive Candida disease in non-neutropenic critical ill patients. Micafungin has a good safety profile (similar to fluconazole). Micafungin is a first line drug for the treatment of invasive Candida disease and may be used as a pre- emptive approach followed by a de-escalating strategy with azoles.</abstract><cop>Spain</cop><pmid>19463281</pmid><doi>10.1016/S1130-1406(09)70012-9</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1130-1406 |
| ispartof | Revista iberoamericana de micología, 2009-03, Vol.26 (1), p.69-74 |
| issn | 1130-1406 |
| language | spa |
| recordid | cdi_proquest_miscellaneous_20684051 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Antifungal Agents - administration & dosage Antifungal Agents - adverse effects Antifungal Agents - therapeutic use Candida Candidiasis - drug therapy Candidiasis - epidemiology Clinical Trials as Topic - statistics & numerical data Critical Care Critical Illness Drug Therapy, Combination Echinocandins - administration & dosage Echinocandins - adverse effects Echinocandins - therapeutic use Fungemia - drug therapy Humans Incidence Leukocyte Count Lipopeptides - administration & dosage Lipopeptides - adverse effects Lipopeptides - therapeutic use Neutrophils Randomized Controlled Trials as Topic - statistics & numerical data |
| title | Clinical use of micafungin for the treatment of invasive candidiasis in critical ill patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T11%3A57%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20use%20of%20micafungin%20for%20the%20treatment%20of%20invasive%20candidiasis%20in%20critical%20ill%20patients&rft.jtitle=Revista%20iberoamericana%20de%20micolog%C3%ADa&rft.au=Pozo-Laderas,%20Juan%20Carlos&rft.date=2009-03-31&rft.volume=26&rft.issue=1&rft.spage=69&rft.epage=74&rft.pages=69-74&rft.issn=1130-1406&rft_id=info:doi/10.1016/S1130-1406(09)70012-9&rft_dat=%3Cproquest_pubme%3E20684051%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20684051&rft_id=info:pmid/19463281&rfr_iscdi=true |